Table 39Evidence summary table for trials of buspirone versus placebo

Buspirone versus placebo
No. trials (total participants)5 RCTs
(N = 806)
Study ID
Benefits (end of treatment)
HAM-ASMD = −0.27 (−0.48, −0.06)
MD = −1.93 (−3.04, −0.82)
K = 4, N = 519
Quality: high
Non-response (≤ 50% reduction in HAM-A)RR = 0.87 (0.74, 1.01)
K = 2, N = 365
Quality: moderate
Non-remission (≥7 on HAM-A)–
Harms (end of treatment)
Discontinuation due to adverse eventsRR = 2.02 (1.12, 3.67)
K = 3, N = 591
Quality: high
NauseaRR = 2.34 (1.53, 3.58)
K = 2, N = 364
Quality: high
InsomniaRR = 1.46 (0.59, 3.66)
K = 1, N = 162
Quality: moderate
DizzinessRR = 3.68 (2.66, 5.08)
K = 4, N = 754
Quality: high

From: 8, PHARMACOLOGICAL AND PHYSICAL INTERVENTIONS

Cover of Generalised Anxiety Disorder in Adults
Generalised Anxiety Disorder in Adults: Management in Primary, Secondary and Community Care.
NICE Clinical Guidelines, No. 113.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2011.
Copyright © 2011, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.